Pakistani Company Inks Deal to Manufacture COVID-19 Vaccine

Pakistani Company Inks Deal to Manufacture COVID-19 Vaccine
Joe Raedle-Getty Images North America—AFP
Searle’s agreement with Livzon Mapharm is linked to a vaccine that is currently in Phase II clinical trials
Pakistani pharmaceutical company Searle has inked a deal with China’s Livzon Mapharm allowing it to license, manufacture, and supply a new COVID-19 vaccine in the country, according to information provided by the company to the Pakistan Stock Exchange.
“Searle Company has concluded an exclusive licensing and supply agreement with Livzon Mapharm Inc. for the Recombinant Novel Coronavirus Vaccine (V-01). The licensing agreement also covers the manufacturing transition of (V-01) in Pakistan,” reads the letter submitted by the company. It said that the vaccines was in the final phases of its clinical trial, adding that early results were promising.

Related Keywords

China ,United States ,Russia ,Pakistan ,America ,Pakistani ,Livzon Mapharm ,Pakistan Stock Exchange ,Livzon Mapharm Inc ,Oxford University Astrazeneca ,Drug Regulatory Authority Of Pakistan ,Searle Company ,Joe Raedle Getty Images North America ,Pakistan Stock ,Recombinant Novel Coronavirus Vaccine ,Recombinant Novel ,Drug Regulatory Authority ,Oxford University ,சீனா ,ஒன்றுபட்டது மாநிலங்களில் ,ரஷ்யா ,பாக்கிஸ்தான் ,அமெரிக்கா ,பாக்கிஸ்தானி ,பாக்கிஸ்தான் ஸ்டாக் பரிமாற்றம் ,மருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான் ,தேடல் நிறுவனம் ,பாக்கிஸ்தான் ஸ்டாக் ,மறுசீரமைப்பு நாவல் ,மருந்து ஒழுங்குமுறை அதிகாரம் ,ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் ,